Postoperative tumor infiltrating lymphocytes treatment for patients with hepatocellular carcinoma
- VernacularTitle:肿瘤浸润性淋巴细胞治疗原发性肝癌的基础与临床研究
- Author:
Sheng HE
;
Gang MAI
;
Mingchen BA
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Lymphocytes,tumor infiltrating;
Antibodies, monoclonal
- From:
Chinese Journal of General Surgery
1993;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of TILs treatment on postoperative patients with hepatocellular carcinoma (HCC) and the in vitro and in vivo hepatic targeting tendency of a compound of Galactosyl-Anti-CD_3McAb-TILs.Methods Thirty postoperative HCC patients were treated with TILs plus rIL-2. A hepatic targeting carrier, Galactosyl-Anti-mouse-CD_3-monoclonal antibody (Gal-Anti-CD_3-McAb), was synthesized.Result It was found that the peripheral blood level of IL-2 and T cell subset increased in all the 30 patients treated by TILs.24 HCC cases undergoing hepatectomy were treated by TILs therapy, and follow-up of 6 to 48 months found no recurrence. In an murine experiment a combination of TIL & Galactosyl-Anti-CD_3McAb-TIL tended to aggregate in lung while infused from peripheral vein. Its hepatic targeting tendency was unremarkable. Conclusion Postoperative use of TILs increased patients’ antitumor immunity, prolongs the survival, while galactosyl-anti-CD_3McAb-TIL does not show a satisfactory hepatic target tendency.
